Showing results (241-250 of 661) with videos related to
Sort By:
Pageof 67
Molecular Cancer Research : MCR|February 27, 2020
Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal CancerAlexandros Georgiou, Adam Stewart, David Cunningham, et al.Perfusion|March 17, 2016
Agreement between ACT and aPTT during extracorporeal membrane oxygenation shows intra- and inter-individual variationDavid Cunningham, Martin W Besser, Kimberly Giraud, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 3, 2009
Inequity of access to implantable cardioverter defibrillator therapy in England: possible causes of geographical variation in implantation ratesJanet M McComb, Christopher J Plummer, Morag W Cunningham, et al.Journal of Lipid Research|December 6, 2005
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionRonald W Clark, Roger B Ruggeri, David Cunningham, et al.European Journal of Cancer (Oxford, England : 1990)|September 30, 2004
Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden HospitalOurania Katopodis, Paul Ross, Andrew R Norman, et al.Journal of Surgical Oncology|January 6, 2015
A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomyKyriakos Neofytou, Alexandros Giakoustidis, Elizabeth C Smyth, et al.The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.Clinical Colorectal Cancer|July 26, 2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal CancerRaghav Sundar, Susana Miranda, Daniel Nava Rodrigues, et al.Current Oncology (Toronto, Ont.)|June 25, 2026
Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated OutcomesPanagiotis Ntellas, Haeseong Park, Kerry Culm, et al.Gut|September 5, 2020
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumoursKate Young, Rita T Lawlor, Chanthirika Ragulan, et al.Pageof 67